These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Extracellular matrix integrity: a possible mechanism for differential clinical effects among selective estrogen receptor modulators and estrogens? Cox DA; Helvering LM Mol Cell Endocrinol; 2006 Mar; 247(1-2):53-9. PubMed ID: 16426741 [TBL] [Abstract][Full Text] [Related]
45. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA; BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496 [TBL] [Abstract][Full Text] [Related]
46. Long-term postmenopausal hormone therapy and endometrial cancer risk: a study by Doherty et al. Odem RR; Moniz MH; Allsworth JE; Bleckman CR; Omicioli VA; Lawrence LT; Thaker PH Am J Obstet Gynecol; 2007 Aug; 197(2):213-4; discussion e1-5. PubMed ID: 17689656 [No Abstract] [Full Text] [Related]
47. Complex endometrial hyperplasia in the context of tibolone administration. Kane SC; Quinn MA Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):338-9. PubMed ID: 19566575 [No Abstract] [Full Text] [Related]
48. Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress? Taylor AL; Adams-Campbell LL; Wright JT J Natl Cancer Inst; 1999 Nov; 91(21):1792-3. PubMed ID: 10547378 [No Abstract] [Full Text] [Related]
49. Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review. Tinelli A; Vergara D; Martignago R; Leo G; Malvasi A; Tinelli R Acta Obstet Gynecol Scand; 2008; 87(11):1101-13. PubMed ID: 18607816 [TBL] [Abstract][Full Text] [Related]
52. Tibolone reduces osteoporotic fracture risk and breast cancer risk, but increases the risk of stroke. de Melo NR; Pompei LM Gynecol Endocrinol; 2010 Feb; 26(2):73-5. PubMed ID: 19995151 [No Abstract] [Full Text] [Related]
53. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. McCullough ML; Patel AV; Patel R; Rodriguez C; Feigelson HS; Bandera EV; Gansler T; Thun MJ; Calle EE Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):73-9. PubMed ID: 18187388 [TBL] [Abstract][Full Text] [Related]
54. [Treatments "substitute" to Hormonal Replacement Therapy of menopause]. Letonturier P Presse Med; 2002 Sep; 31(28):1313. PubMed ID: 12374102 [No Abstract] [Full Text] [Related]
55. The safety of tibolone in epithelial ovarian cancer patients. Lee KB; Lee JM; Yoon JH; Park CY Maturitas; 2006 Sep; 55(2):156-61. PubMed ID: 16563669 [TBL] [Abstract][Full Text] [Related]
56. Clomiphene citrate causes aberrant tubal apoptosis and estrogen receptor activation in rat fallopian tube: implications for tubal ectopic pregnancy. Shao R; Nutu M; Weijdegård B; Egecioglu E; Fernandez-Rodriguez J; Karlsson-Lindahl L; Gemzell-Danielsson K; Bergh C; Billig H Biol Reprod; 2009 Jun; 80(6):1262-71. PubMed ID: 19211805 [TBL] [Abstract][Full Text] [Related]
57. Hormone replacement therapy and the endometrium. Daayana S; Holland CM Menopause Int; 2009 Sep; 15(3):134-8. PubMed ID: 19723685 [TBL] [Abstract][Full Text] [Related]
58. Bone builder vs. breast cancer. Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):1-2. PubMed ID: 17323491 [No Abstract] [Full Text] [Related]
59. Reproductive factors and the risk of endometrial cancer. Ali AT Int J Gynecol Cancer; 2014 Mar; 24(3):384-93. PubMed ID: 24463639 [TBL] [Abstract][Full Text] [Related]
60. Toremifene: an evaluation of its safety profile. Harvey HA; Kimura M; Hajba A Breast; 2006 Apr; 15(2):142-57. PubMed ID: 16289904 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]